Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) has announced the appointment of Dr. Anh Nguyen as the Chief Medical Officer (CMO), succeeding Ken Johnson, PharmD, SVP Global Development and Medical Affairs, who is set to retire on April 1, 2025. Dr. Nguyen, who will report to John Shannon, Xeris' CEO, will be responsible for leading the entire product portfolio vision and strategic direction for the medical, regulatory, preclinical and clinical development, and pharmacovigilance functions.
Dr. Anh Nguyen brings significant experience to his role as CMO, having led the development of first-in-class therapies including circular RNA-based oncology treatments, gene-edited xenotransplants, immuno-oncology vaccines, and allogeneic CAR-T therapies. His previous roles include serving as Vice President and Therapeutic Sector Lead at Asklepios Biopharmaceutical (AskBio) and contributing to landmark policies such as the "21st Century Cures Act" during his Robert Wood Johnson Foundation Health Policy Fellowship serving on the US Senate HELP Committee.
During his previous tenure at Xeris, Dr. Nguyen served as the program medical lead for Gvoke®'s NDA and MAA approvals and multiple IND clearances for endocrine and rare diseases, including novel endocrine drug co-formulations for diabetes, immunology, and pediatric epilepsy. Dr. Nguyen holds an MBA from the University of Chicago, an MD from Rutgers New Jersey Medical School, and completed his residency and fellowship training in anesthesiology and cardiovascular anesthesia at Massachusetts General Hospital, Harvard Medical School.
Ken Johnson, PharmD, expressed confidence in Dr. Nguyen's ability to lead Xeris to new levels of success, stating that it has been an honor to be part of an exceptionally talented team and a privilege to help lead Xeris through its evolution to a commercial-stage biopharmaceutical company.
Xeris Biopharma Holdings, Inc. is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. The company has three commercially available products: Recorlev® for the treatment of endogenous Cushing's syndrome, Gvoke® a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, and Keveyis® a proven therapy for primary periodic paralysis. Additionally, Xeris has a pipeline of development programs led by XP-8121, a phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris' technology platforms, XeriSol® and XeriJect®, for its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. The market has reacted to these announcements by moving the company's shares 0.8% to a price of $3.78. Check out the company's full 8-K submission here.
